1. Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy. a) 162 patients followed for a median of 36 months.
Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy. a) 162 patients followed for a median of 36 months. Reproduced from [5] with permission from the publisher. b) 178 patients followed for a median of 26 months. Reproduced from [6] with permission from the publisher.
J-L. Vachiéry et al. Eur Respir Rev 2012;21:40-47
©2012 by European Respiratory Society